RAD51 and breast carcinoma: In a cohort of 13 BRCAMUT breast cancer PDXs treated with olaparib, the baseline proportion of RAD51-high cells was higher amongst PARPi-sensitive tumors in comparison to PARPi-resistant tumors (24% versus 3%, p = 0.0025) [129].